drugset
drugset / Trial / NCT07385846

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

NCT07385846 ↗

Phase 1 Not yet recruiting 8 enrolled Jennifer Leddon NaviFUS Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.

Timeline

Start
2026-06-01
Primary completion
2028-06-01
Completion
2030-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg —

Indications

glioblastoma